Today: 7 February 2026
Subscribe

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

New York, Jan 7, 2026, 11:50 a.m. EST — Regular session Shares of Structure Therapeutics Inc rose 5.6% to $66.75 in late-morning trade on Wednesday, recovering from early swings as investors sized up a newly disclosed patent license deal tied to Roche and Genentech’s oral obesity drug effort. The agreement matters because it puts near-term cash on the table for a clinical-stage biotech and suggests its intellectual property has value beyond its own pipeline, at a moment when markets are quick to price any edge in the crowded GLP-1 weight-loss race. A Form 8-K filing showed the company’s Gasherbrum Bio
7 January 2026
···
Bloom Energy stock jumps as $600 million Wells Fargo credit line and $502 million Quanta microgrid deal draw fresh attention

Bloom Energy stock jumps as $600 million Wells Fargo credit line and $502 million Quanta microgrid deal draw fresh attention

NEW YORK, Jan 7, 2026, 11:43 EST — Regular session Bloom Energy Corp (NYSE: BE) shares rose 8.1% to $111.38 on Wednesday, lifting off an intraday low of $100.87, as investors refocused on a new $600 million bank line and a large fuel-cell microgrid purchase linked to Quanta. The stock hit an intraday high of $111.41 and traded more than 8.3 million shares by late morning, keeping the $100 level in play for traders after the early slide. The move matters because Bloom has become a sensitive read-through on on-site power demand, a corner of the market that has drawn
7 January 2026
·····
Oracle stock (ORCL) barely moves as Jefferies sticks with $400 target

Oracle stock (ORCL) barely moves as Jefferies sticks with $400 target

New York, January 7, 2026, 11:40 ET — Regular session Oracle Corp shares slipped 0.2% to $193.44 in late-morning trading on Wednesday, after Jefferies reiterated a Buy rating and kept a $400 price target in a 2026 software outlook. Jefferies analyst Brent Thill said OpenAI accounts for 57% of Oracle’s contract backlog and argued the stock can rebound after a roughly 40% slide tied to worry about AI spending and debt. Investors The call matters because Oracle has become a test case for how much the market will pay for AI infrastructure inside a mature software name. Investors want proof
7 January 2026
·····
Chevron stock edges higher as $22 billion Lukoil-bid talk collides with Venezuela supply headlines

Chevron stock edges higher as $22 billion Lukoil-bid talk collides with Venezuela supply headlines

New York, Jan 7, 2026, 11:28 EST — Regular session Chevron Corp shares inched up on Wednesday as investors digested a report that private equity group Quantum Energy Partners is working on a bid that could involve Chevron for the international assets of Russia’s Lukoil, even as weaker oil prices kept a lid on energy stocks more broadly. The stock was up 0.1% at $156.68 by late morning in New York, after trading between $155.19 and $159.60; Exxon Mobil was down about 1.2%, ConocoPhillips fell 1.3% and Occidental Petroleum slid 1.5%. Reuters The timing matters. A possible transaction for sanctioned-era
7 January 2026
··
AppLovin (APP) stock rises as Piper Sandler sticks with $800 target and BofA keeps $860 view

AppLovin (APP) stock rises as Piper Sandler sticks with $800 target and BofA keeps $860 view

New York, January 7, 2026, 11:36 EST — Regular session AppLovin (APP.O) shares rose about 2% on Wednesday, building on a choppy start to the year as fresh analyst notes kept attention on the company’s push into e-commerce advertising. The stock was up at $629.57, while the S&P 500 was little changed and the Nasdaq-100 ETF edged higher; rival Trade Desk fell. The move matters because AppLovin’s next leg is still being priced in. Bulls are betting the company can broaden beyond mobile-game ads into web and e-commerce budgets, and the next earnings call is expected to put real numbers
7 January 2026
·····
Regencell Bioscience stock jumps 27% again as RGC’s wild swings draw momentum traders

Regencell Bioscience stock jumps 27% again as RGC’s wild swings draw momentum traders

New York, Jan 7, 2026, 10:56 EST — Regular session Regencell Bioscience Holdings Limited shares jumped about 27% to $41.90 in morning trading on Wednesday, extending a sharp two-day run for the Nasdaq-listed microcap. The stock has swung between $34.11 and $43.74 so far in the session, with nearly 1.0 million shares traded. Why it matters now: the move builds on Tuesday’s 22% gain and keeps Regencell near the top of the day’s high-volatility names, even by small-cap standards. The stock closed at $33.03 on Tuesday after trading as high as $35.68, following a $27.00 close on Monday. StockAnalysis The
7 January 2026
··
SoFi stock slips again as share-sale overhang hangs on; Jan. 30 earnings next

SoFi stock slips again as share-sale overhang hangs on; Jan. 30 earnings next

NEW YORK, Jan 7, 2026, 11:26 (EST) — Regular session SoFi Technologies shares were down about 1.4% at $26.61 by 11:26 a.m. EST on Wednesday, extending recent weakness as investors absorbed fresh details on stock sold into the market. A regulatory filing showed the underwriters of SoFi’s December share sale exercised their option to buy additional stock, and the company completed that extra issuance on Jan. 5. The “greenshoe” option — a standard clause that lets banks buy more shares — pushed total shares sold in the offering to 57,754,660 at $27.50 each, with Goldman Sachs, BofA Securities, Citigroup, Deutsche
7 January 2026
····
Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next

Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next

New York, Jan 7, 2026, 11:10 EST — Regular session Shares of Abivax SA jumped 7.3% to $127.75 in morning trading on Wednesday, after touching a session high of $128.87 and a low of $119.48. Trading volume topped 700,000 shares. The French biotech’s U.S.-listed stock has become a fast-moving name for healthcare traders, in part because its valuation rests on a single late-stage drug program. Its American depositary shares, or ADSs, are U.S.-traded certificates that represent ownership of a foreign company’s shares. Abivax is developing obefazimod, an oral treatment candidate for ulcerative colitis, a chronic inflammatory bowel disease. The company
7 January 2026
·····
UMC stock jumps near 10% after December sales update as January earnings near

UMC stock jumps near 10% after December sales update as January earnings near

NEW YORK, January 7, 2026, 11:07 EST — Regular session United Microelectronics’ U.S.-listed shares surged on Wednesday, pushing the Taiwan chipmaker to a fresh 52-week high and putting the stock among the session’s top semiconductor gainers. UMC was up about 9.7% at $8.91 in late morning trade. The move matters because UMC’s monthly sales are one of the first hard reads on foundry demand going into 2026, when investors are trying to pin down whether the industry has truly worked through excess inventory. Chip stocks have also caught a bid this week after upbeat signals elsewhere in the sector, including
7 January 2026
·····
Frontline (FRO) stock jumps as Venezuela tanker seizures stir oil-shipping bets

Frontline (FRO) stock jumps as Venezuela tanker seizures stir oil-shipping bets

New York, Jan 7, 2026, 11:12 EST — Regular session Frontline plc (FRO.N) shares rose about 7.7% to $23.27 by 11:12 a.m. EST on Wednesday, after swinging between $21.69 and $23.48 in early trading. The move came as traders leaned into crude-tanker names after the United States said it had seized a Venezuela-linked tanker that had been reflagged under Russia, part of a wider effort to choke off sanctioned oil movements. Crackdowns like that can squeeze the pool of “clean” ships available for mainstream cargoes, a setup that can lift spot freight rates quickly. Reuters Venezuela was loading crude only
7 January 2026
····
UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

New York, January 7, 2026, 11:10 EST — Regular session UnitedHealth Group Incorporated shares fell more than 2% on Wednesday, tracking a broader retreat in managed-care insurers. The stock was down $8.53 at $340.44 in late morning trading, while Humana slid 1.4% and Cigna dropped 2.1%. The move comes with investors bracing for UnitedHealth’s full-year results later this month, when the company is due to set out 2026 guidance. A key focus is the medical care ratio — the share of premium revenue that goes to medical claims — after a stretch of elevated utilization across the sector. UnitedHealth Group
7 January 2026
··········
Lam Research stock slips after two-day rally as traders weigh fresh Buy call and CES headlines

Lam Research stock slips after two-day rally as traders weigh fresh Buy call and CES headlines

NEW YORK, Jan 7, 2026, 10:51 EST — Regular session Shares of Lam Research Corp (LRCX) fell about 2.5% to $201.86 in morning trading on Wednesday, giving back part of a two-day rally in semiconductor equipment stocks. The timing matters because the trade in chip gear has turned fast this week, with investors leaning into names tied to artificial-intelligence-related chip buildouts as CES kicks off in Las Vegas. The group has also started to draw fresh analyst attention ahead of earnings season. Reuters+1 Aletheia Capital on Tuesday initiated coverage of Lam with a Buy rating and a $260 price target.
7 January 2026
·····
1 … 858 859 860 861 862 … 2,711

Stock Market Today

Anglo American share price slips as BofA turns neutral after copper outlook cut

Anglo American share price slips as BofA turns neutral after copper outlook cut

7 February 2026
Anglo American shares closed down 0.75% at 3,435 pence Friday after BofA Global Research downgraded the miner to “neutral” and raised its price target to 3,600 pence. Anglo cut its 2026 copper production guidance and warned of continued weakness at De Beers. The company expects $200 million in charges tied to its Chile copper operations in the second half of 2025.
Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

7 February 2026
Amazon shares fell Friday after the company announced a $200 billion AI infrastructure plan for 2026, exceeding analyst expectations and reviving investor concerns about profitability. Combined 2026 capex flagged by Amazon, Alphabet, Microsoft, and Meta now tops $630 billion. Nvidia, AMD, and Broadcom shares surged on the news, while software and data firms remained under pressure.
Go toTop